Please login to the form below
oxycodone
This page shows the latest oxycodone news and features for those working in and with pharma, biotech and healthcare.
FDA committee rejects Intellipharmaceutics’ opioid drug Aximris
Verdict closely follows rejection of Nektar’s opioid analgesic. The FDA’s Anesthetic and Analgesic Committee has rejected yet another opioid drug – this time Intellipharmaceutics’ extended-release oxycodone tablet Aximiris. . ... Aximris was
Latest news
-
FDA awards another non-opioid pain drug breakthrough status
Meanwhile one company, Purdue Pharma, has become increasingly identified for fuelling the epidemic with its opioid products, especially OxyContin, a timed-release formulation of opioid pain medication oxycodone.
-
Making a list and checking it twice…
And about making it more difficult to distribute fentanyl and oxycodone-based drugs.
-
FDA panel backs Pfizer and Teva abuse-resistant painkillers
The panel also voted by nine votes to six in favour of approving Pfizer's Troxyca ER (oxycodone/naltrexone) for the sane indication. ... Committee members were swayed by the FDA reviewer's report on Troxyca ER however, which concluded that it was
-
FDA approves Adapt Pharma's opioid overdose nasal spray
The dangers come from prescriptions opioids such as morphine, codeine, methadone and oxycodone as well as illicit opioids like heroine and heroin/fentanyl mixes.
-
Grunenthal and AcelRx’s Zalviso approved in EU
is also heating up as additional potential competitors include the fentanyl transdermal system IONSYS developed by Johnson and Johnson and MoxDuo, an orally administered combination of morphine and oxycodone being developed
More from news
Approximately 2 fully matching, plus 21 partially matching documents found.
Latest Intelligence
-
The transatlantic opioid crisis
A landmark ruling by a judge in Oklahoma, USA awarded the state record damages of $572m (£468m) from Johnson &Johnson (J&J), the manufacturer of synthetic opioids like oxycodone and fentanyl
-
Pharma deals during November 2013
The licence is for tamper resistant oxycodone (marketed in the US since 2010) and an oxycodone/naloxone combination marketed in Europe since 2009.
-
Pharma deals during October 2012
34. ††QRxPharma / Paladin Labs. Licence. MoxDuo IR, fixed dose morphine and oxycodone for pain (NDA filed).
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Group Account Director, Healthcare Advertising/ Brand comms, Lon...
-
8 month contract up to £90K
-
Account Management
-
Competitive Salary Offered
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
-
Senior Account Executive
-
Competitive Salary
-
Publications Director
-
Competitive Salary
-
Associate Account Director
-
Competitive Salary
- Senior & Principal Medical Writer
-
Competitive Salary Offered
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
-
Senior Medical Writer
-
Competitive Salary
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
-
Medical Editor
-
Competitive Salary
- Head of Strategic Planning, Healthcare Advertising/ Brand comms,...
-
Six figure salary
- Account Manager - Creative Healthcare Communications - South Wes...
-
Excellent Remuneration
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Senior Account Manager/ Account Director
-
Competitive Salary Offered
-
Account Manager
-
Competitive Salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Novavax is close to finalising a COVID-19 vaccine supply deal with the EU
- CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval
- GSK’s revenue drops by 18% in Q1 as performance pressures mount
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- Single dose of COVID-19 vaccines ‘significantly’ reduces infections
- Novartis partners with Bill & Melinda Gates Foundation on ‘accessible’ sickle cell gene therapy
- Nanobiotechnology, Artificial Intelligence, and Virtual Care
- Virtual Trials, Remote Care, & Cross-Border Collaboration: Ethical & Legal Challenges
- Live Webinar: Blockchain in Healthcare: Predictions for the Post-COVID World
- Live Webinar: Digital Health for Improving Care in Disadvantaged Populations
- How can we strike the right balance between familiarity and innovation when it comes to data presentation?
- Illingworth Research Group wins ‘prestigious’ Queen’s Award
- Working in true partnership in a time of change
- Live Webinar: The Future of Digital Pills
- Total COVID-19 vaccine spending to reach $157bn by 2025, says report
- NICE sets out plans for ‘ambitious’ five-year strategy
- Pfizer CEO says oral COVID-19 pill could be ready by the end of the year
- PMEA 2021 has officially launched – with a new online entry system
PMHub
McCann Health Medical Communications
We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....
Latest intelligence
- How can we strike the right balance between familiarity and innovation when it comes to data presentation?
- Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
- Deep 6 AI: the smart software breathing new life into clinical trials
- Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
- COVID-proof: How Teams are Creating Launch Intensity thru Adversity
- Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....
